Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC)

被引：0
|
作者：
Molife, Rhoda
Dearnaley, David
Parker, Chris
Patterson, Stephen
Riggs, Charles
Higano, Celestia
Stadler, William M.
McCulloch, William
Shalaurov, Alex
de Bono, Johann
机构：
[1] Royal Marsden Hosp, Drug Dev Unit, Sutton SM2 5NG, Surrey, England
[2] Royal Marsden Hosp, Acad Urol Unit, Sutton SM2 5NG, Surrey, England
[3] Univ S Florida, H Lee Moffitt Canc Ctr, Genitourinary Oncol Program, Tampa, FL 33682 USA
[4] Univ Florida, Dept Med, Gainesville, FL 32611 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Gloucester Pharmaceut Inc, Med & Regulatory, Cambridge, MA USA
[8] Charles Rivers Labs, Cary, NC USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [1] Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)
    Parker, C.
    Molife, R.
    Karavasilis, V.
    Reid, A.
    Patterson, S. G.
    Riggs, C.
    Higano, C.
    Stadler, W. M.
    McCulloch, W.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [3] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [4] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
    George, DJ
    Gockerman, JP
    Petros, W
    Haley, S
    Franklin, AD
    Creel, PA
    Turner, AG
    Sleep, D
    Hurwitz, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 419S - 419S
  • [6] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A randomized dose-finding phase II study of ifosfamide (IF) in metastatic hormone-refractory prostate cancer (HRPC).
    Hervonen, P
    Lehtinen, T
    Tammela, TLJ
    Kellokumpu-Lehtinen, P
    ANNALS OF ONCOLOGY, 2000, 11 : 76 - 76
  • [8] Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    DeJager, R.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H. B.
    Earhart, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [9] A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)
    Hervonen, P
    Lehtinen, T
    Tammela, TL
    Kellokumpu-Lehtinen, P
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (02) : 177 - 180
  • [10] Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)
    Nilsson, S.
    Franzen, L.
    Tyrrel, C.
    Blom, R.
    Tennvall, J.
    Lennernas, B.
    Johannessen, D. C.
    Sokal, M.
    Parker, C.
    Bruland, O. S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 295 - 295
12345